Actively Recruiting

Age: 18Years - 100Years
All Genders
NCT06727981

First-Line and Neoadjuvant Immunotherapy for Gastric Cancer

Led by Qilu Hospital of Shandong University · Updated on 2024-12-11

500

Participants Needed

1

Research Sites

313 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This prospective observational study aims to evaluate the efficacy and safety of immune checkpoint inhibitors as first-line and neoadjuvant therapy for advanced gastric cancer, while also investigating relevant biomarkers to better understand their role in immunotherapy outcomes

CONDITIONS

Official Title

First-Line and Neoadjuvant Immunotherapy for Gastric Cancer

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years old or above
  • Diagnosed with advanced gastric cancer or locally advanced gastric cancer
  • Have not received any previous anti-tumor therapy
  • Planned to receive immunotherapy as first-line or neoadjuvant treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Adequate organ function
Not Eligible

You will not qualify if you...

  • Contraindications to immunotherapy
  • Previous anti-tumor treatments including immunotherapy and chemotherapy
  • History of active immune deficiency or autoimmune diseases, including HIV positive test, or other acquired/congenital immune deficiencies, or history of organ transplantation
  • Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral treatment, including tuberculosis
  • History of active tuberculosis infection within 1 year before recruitment unless treatment was completed
  • History of allogeneic stem cell transplantation or organ transplantation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Qilu Hospital of Shandong University

Jinan, Shandong, China, 250012

Actively Recruiting

Loading map...

Research Team

L

Lian Liu, MD

CONTACT

S

Song Li, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

First-Line and Neoadjuvant Immunotherapy for Gastric Cancer | DecenTrialz